ALLR: Allarity Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
20 institutions reported holding $1.59M of Allarity Therapeutics, Inc. on Form 13F (14 the quarter before). 8 opened a new position and 2 sold out. Shares held by institutions: +29%.
| Largest holders | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 331,509 | $428K |
| VANGUARD CAPITAL MANAGEMENT LLC | 171,795 | $222K |
| GEODE CAPITAL MANAGEMENT, LLC | 154,867 | $200K |
| STATE STREET CORP | 137,600 | $178K |
| Militia Capital Management LLC | 98,978 | $128K |
| CITADEL ADVISORS LLC | 91,748 | $118K |
| VANGUARD FIDUCIARY TRUST CO | 74,913 | $97K |
| NORTHERN TRUST CORP | 36,534 | $47K |
| JANE STREET GROUP, LLC | 36,021 | $46K |
| TWO SIGMA INVESTMENTS, LP | 27,492 | $35K |
Clinical trial readouts
1 Phase 2 or 3 trials by Allarity Therapeutics, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03 (est.) | 2X-121 | Advanced Ovarian Cancer | Phase 2 | 40 | Recruiting | NCT03878849 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.